Clinical Trial Update: Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating chidamide plus decitabine and an anti-PD-1 antibody in patients with relapsed/refractory classical Hodgkin lymphoma who are …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Anti-PD-1 antibody (unspecified)
• Chidamide (chidamide)
• Decitabine (Decitabine)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING